Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease
Study sponsor: Amylyx Pharmaceuticals Inc. · AMLX
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2020-10-22Actual
Enrollment · participants95Actual
Source updated2025-03-07Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.